10 completed. 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 10 |
Follow dalcetrapib: new trials by email Literature Review of dalcetrapib trials Research Report on dalcetrapib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 Dalcetrapib, Placebo - Covid19 | Phase 2 | Completed | DalCor Pharmaceuticals | 227 | 2021-01-11 | 2022-12-07 |
| A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease Dalcetrapib (RO4607381), Placebo - Coronary Heart Disease | Phase 2 | Completed | Hoffmann-La Roche | 130 | 2008-03-01 | 2020-01-03 |
| A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients Placebo, dalcetrapib - Coronary Heart Disease | Phase 2 | Completed | Hoffmann-La Roche | 476 | 2008-02-01 | 2020-01-02 |
| A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 dalcetrapib (RO4607381), placebo - Coronary Heart Disease | Phase 2 | Completed | Hoffmann-La Roche | 77 | 2007-01-01 | 2020-01-03 |
| A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent. Placebo, dalcetrapib - Coronary Heart Disease | Phase 2 | Completed | Hoffmann-La Roche | 135 | 2006-07-01 | 2020-01-27 |
| A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C) Placebo, Pravastatin, Dalcetrapib - Dyslipidemia | Phase 2 | Completed | Hoffmann-La Roche | 292 | 2005-07-01 | 2020-01-02 |
| Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels JTT-705 600 mg and simvastatin 40 mg, Placebo and simvastatin 40 mg - Dyslipidemia | Phase 2 | Completed | Akros Pharma Inc. | 92 | 2004-02-01 | 2008-06-03 |
| Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels JTT-705 600 mg and atorvastatin 20 mg, Placebo and atorvastatin 20 mg - Dyslipidemia | Phase 2 | Completed | Akros Pharma Inc. | 105 | 2004-01-01 | 2008-06-03 |
| Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia JTT-705 600 mg and pravastatin 40 mg, JTT-705 300 mg and pravastatin 40 mg, Placebo and pravastatin 40 mg - Type II Hyperlipidemia | Phase 2 | Completed | Akros Pharma Inc. | 155 | 2002-06-01 | 2008-06-03 |
| Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia Placebo, JTT-705 300mg, JTT-705 600mg - Type II Hyperlipidaemia | Phase 2 | Completed | Japan Tobacco Inc. | 198 | 2000-05-01 | 2008-05-29 |
Coronary Disease (4) · Dyslipidemias (3) · Hyperlipoproteinemia Type II (2) · COVID-19 (1)
Hoffmann-La Roche (5) · Akros Pharma Inc. (3) · DalCor Pharmaceuticals (1) · Japan Tobacco Inc. (1)
Netherlands (5) · United States (4) · Canada (2) · Germany (2) · Austria (1) · France (1) · Italy (1) · Switzerland (1) · United Kingdom (1)
David Kallend (1)
PMID 21128879, PMID 21908036, PMID 22345126, PMID 23942908, PMID 24135322